EVENTS | VIEW CALENDAR
Prometic, Sartorius expand technology transfer deals in Asia
AUBAGNE, FranceóProMetic Life Sciences Inc. and Sartorius Stedim Biotech have launched several technology transfer deals in Asia stemming from the companies' original collaboration in 2006 to supply technology, filtration equipment and consumables to plasma fractionators.
ProMetic has signed a strategic alliance and license agreement with the Wuhan Institute of Biological Products, giving Wuhan exclusive access to ProMetic's yield-improving plasma protein process for the Chinese market. In addition, ProMetic has signed agreements with Taiwanese biotechnology company Blue-Blood Biotech Corp. for the development and commercialization of human plasma-derived specialty immunoglobulin preparations for the treatment of several infectious diseases, including cytomegalovirus and enterovirus.
Under this agreement, ProMetic Pierre Laurin, president and CEO of ProMetic, says the company's previous and new agreements will make ProMetic's protein technologies business EBITDA-positive this year and generate an EBITDA of $15 to $20 million in 2009.
"Collectively, these agreements have firmly established ProMetic's technology in Asia and provide an opportunity to generate an estimated $60 million in annual product sales and royalties for ProMetic, with the first plasma-derived products expected to be commercialized in 2011 in Asia and in North America."
Dr. Uwe Gottschalk, vice president of purification technologies at Sartorius, says his company expects significant sales from the collaboration.
"This association allows us to combine ProMetic's proprietary technology and Sartorius' integrated technology portfolio to bypass current bioseparation limitations," Gottschalk says. "In doing so, we generate increased yields for plasma-derived proteins and therefore enhance the profitability of the existing processes at our customers."